PI3K/AKT pathway inhibitors, such as the AKT inhibitor MK2206 and PI3K inhibitors LY294002 and BKM120, have been demonstrated to be effective to inhibit proliferation and growth in ARID1A-loss cancer cells (154, 155). This evidence concerns the gene PIK3CA and cancer.